Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory

Patient Education and Counseling

Volumn 96, Issue 1, 2014, Pages 106-112

  Ralph, Angelique F ^a   Ager, Brittany ^a   Bell, Melanie L ^a,b   Collins, Ian M ^c   Andrews, Lesley ^d   Tucker, Kathy ^d   Phillips, Kelly Anne ^c,e   Butow, Phyllis ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF ARIZONA   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BRCA1; Breast cancer; Chemoprevention; Patient preferences; Protection motivation theory; SERMs

Indexed keywords

SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG PREFERENCE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION; VULNERABLE POPULATION; ATTITUDE TO HEALTH; BEHAVIOR; BREAST NEOPLASMS; DECISION MAKING; GENETICS; MIDDLE AGED; MOTIVATION; PATIENT PREFERENCE; PSYCHOLOGICAL MODEL; PSYCHOLOGY; REGRESSION ANALYSIS;

ADULT; AUSTRALIA; BREAST NEOPLASMS; DECISION MAKING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTENTION; MIDDLE AGED; MODELS, PSYCHOLOGICAL; MOTIVATION; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE; REGRESSION ANALYSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84902157836     PISSN: 07383991     EISSN: 18735134     Source Type: Journal    
DOI: 10.1016/j.pec.2014.04.011     Document Type: Article

References (53)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parklin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. McPherson K., Steel C., Dixon J. ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics. Brit Med J 2000, 321:624.
3. Beral V., Bull D., Doll R., Peto R., Reeves G. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 women without the disease. Lancet 2001, 358:1389-1399. Collaborative Group on Hormonal Factors in Breast C.
4. Antoniou A., Pharoah P.D.P., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
5. Cuzick J., Sestak I., Bonanni B., Costantino J.P., Cummings S., DeCensi A., et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013, 381:1827-1834.
6. Goss P.E., Ingle J.N., Alés-Martínez J.E., Cheung A.M., Chlebowski R.T., Wactawski-Wende J., et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364:2381-2391.
7. Savage L. Researchers wonder why high-risk women are not taking chemoprevention drugs. J Natl Cancer Inst 2007, 99:913-914.
8. Vogel V.G. Tipping the balance for the primary prevention of breast cancer. J Natl Cancer Inst 2010, 102:1683-1685.
9. Evans D.G.R., Lalloo F., Shenton A., Boggis C., Howell A. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 2001, 358:889-890.
10. Keogh L.A., Hopper J.L., Rosenthal D., Phillips K.A. Australan clinicians and chemoprevention for women at high familial risk for breast cancer. Hered Cancer Clin Pract 2009, 7.
11. Collins I.M., Milne R.L., Weideman P., McLachlan S.A., Friedlander M.L., kConFab Investigators, et al. Preventing breast and ovarian cancer in women at highest risk: long-term follow-up of women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Med J Aust 2013, 199:680-683.
12. Freedman A.N., Graubard B.I., Rao S.R., McCaskill-Stevens W., Ballard-Barbash R., Gail M.H. Estimates of the number of US women who could benefit from tamoxifen. J Natl Cancer Inst 2003, 95:526-532.
13. Waters E.A., Cronin K.A., Graubard B.I., Han P.K., Freedman A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among US women. Cancer Epidemiol Biomarkers Prev 2010, 19:443-446.
14. Bishop J.F., Glass P., Pezzullo M.L., Taylor P.S., Moore P.T., Parkinson B.T., et al. The health economics of chemoprevention for breast cancer in Australia 2008, Cancer Institute NSW, NSW.
15. Land S.R., Wickerham D.L., Costantino J.P., Ritter M.W., Vogel V., Myoungkeun L., et al. Patient-reported symptoms and quality of life during treatment with Tamoxifen and Raloxifene for breast cancer prevention. The NSABP study of Tamoxifen and Raloxifene (STAR) P-2 Trial. J Am Med Assoc 2006, 295:2742-2751.
16. Port E.R., Montgomery L., Heerdt A., Borgen P.I. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001, 8:580-585.
17. Visvanathan K., Hurley P., Bantug E., Brown P., Col N.F., Cuzick J., et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2013, 31:2942-2962.
18. Rosenstock I.M. The health belief model and preventive health behavior. Health Educ Behav 1974, 2:354-386.
19. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process 1991, 50:179-211.
20. Rogers R.W. Cognitive and physiological processes in fear appeals and attitude change: a revised theory of protection motivation. Social psychophysiology 1983, Guillford Press, New York. J.T. Cacioppo, R.E. Petty (Eds.).
21. Rogers R.W. A protection motivation theory of fear appeals and attitude change. J Psychol 1975, 91:93.
22. Boer H., Seydel E.R. Protection motivation theory. Predicting health behaviour: research and practice with social cognition models 2005, 81-126. Open University Press, Maidenhead. M. Conner, P. Norman (Eds.).
23. Orbell S., Sheeran P. 'Inclined abstainers': a problem for predicting health-related behaviour. Br J Soc Psychol 1998, 37:151-165.
24. Trafimow D., Sheeran P., Conner M., Finlay K.A. Evidence that perceived behavioural control is a multidimensional construct: perceived control and perceived difficulty. Br J Soc Psychol 2002, 41:101-121.
25. Conner M., Norman P. Predicting health behaviour: a social cognition approach 2005, 1-27. Open University Press, London.
26. Floyd D.L., Prentice-Dunn S., Rogers R.W. A meta-analysis of research on protection motivation theory. J Appl Soc Psychol 2000, 30:407-429.
27. Milne S., Sheeran P., Orbell S. Prediction and intervention in health-related behavior: a meta-analytic review of protection motivation theory. J Appl Soc Psychol 2000, 30:106-143.
28. National Breast and Ovarian Cancer Centre Breast cancer risk factors: a review of the evidence 2009, Australian Government Department of Health and Ageing, Sydney.
29. Champion V.L., Skinner C.S., Menon U., Rawl S., Giesler R.B., Monahan P., et al. A breast cancer fear scale: psychometric development. J Health Psychol 2004, 9:753-762.
30. Morrison V., Henderson B.J., Taylor C., Dafydd N.A.C., Unwin A. The impact of information order on intentions to undergo predictive genetic testing. J Health Psychol 2010, 15:1082-1092.
31. Cyrus-David M., Strom S. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psychooncology 2001, 10:521-533.
32. Bober S.L., Hoke L.A., Duda R.B., Regan M.M., Tung N.M. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004, 22:4951-4957.
33. Kent G., Howie H., Fletcher M., Newbury-Ecob R., Hosie K. The relationship between perceived risk, thought intrusiveness and emotional well-being in women receiving counselling for breast cancer risk in a family history clinic. Br J Health Psychol 2000, 5:15-26.
34. Hosmer D.W., Lemeshow S. Applied logistic regression 2000, Wiley, Brisbane.
35. Lovegrove E., Rumsey N., Harcourt D., Cawthorn S. Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer. Psychooncology 2000, 9:193-202.
36. Tchou J., Hou N., Rademaker A., Jordan V.C., Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004, 100:1800-1806.
37. Metcalfe K., Poll A., O'connor A., Gershman S., Armel S., Finch A., et al. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet 2007, 72:208-217.
38. Meiser B., Butow P., Price M., Bennett B., Berry G., Tucker K. Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health 2003, 12:769-778.
39. Heisey R., Pimlott N., Clemons M., Cummings S., Drummond N. Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician 2006, 52.
40. Sheeran P. Intention-behavior relations: a conceptual and empirical review. Eur Rev Soc Psychol 2002, 12:1-36.
41. Buckner E.H.C. Utility of protection motivation theory as a model for evaluating women's compliance with monthly breast self-examination 1991, George Mason University.
42. Bunn J.Y., Bosompra K., Ashikaga T., Flynn B.S., Worden J.K. Factors influencing intention to obtain a genetic test for colon cancer risk: a population-based study. Prev Med 2002, 34:567-577.
43. Black W.C., Nease R.F., Tosteson A.N.A. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 1995, 87:720-731.
44. Davis S., Stewart S., Bloom J. Increasing the accuracy of perceived breast cancer risk: results from a randomized trial with Cancer Information Service callers. Prev Med 2004, 39:64-73.
45. Lerman C., Lustbader E., Rimer B., Daly M., Miller S., Sands C., et al. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst 1995, 87:286-292.
46. Hopwood P. Breast cancer risk perception: what do we know and understand?. Breast Cancer Res 2000, 2:387.
47. Norman P., Boer H., Seydel E.R. Protection motivation theory. Predicting health behaviour: Research and practice with social cognition models. 2005, 81-126. Open University Press, Maidenhead. 2nd Edition. M. Conner, P. Norman (Eds.).
48. Abraham C.S., Sheeran P., Abrams D., Spears R. Exploring teenagers' adaptive and maladaptive thinking in relation to the threat of HIV infection. Psychol Health 1994, 9:253-272.
49. Helmes A.W. Application of the protection motivation theory to genetic testing for breast cancer risk. Prev Med 2002, 35:453-462.
50. Meiser B., Butow P., Friedlander M., Schnieden V., Gattas M., Kirk J., et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 2000, 18:2250-2257.
51. Coyne J.C., Anderson K.K. Marital status, marital satisfaction, and support processes among women at high risk for breast cancer. J Fam Psychol 1999, 13:629.
52. Coyne J.C., Benazon N.R., Gaba C.G., Calzone K., Weber B.L. Distress and psychiatric morbidity among women from high-risk breast and ovarian cancer families. J Consult Clin Psychol 2000, 68:864.
53. Cull A., Miller H., Porterfield T., Mackay J., Anderson E., Steel C., et al. The use of videotaped information in cancer genetic counselling: a randomized evaluation study. Br J Cancer 1998, 77:830.